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Purpose  
• To demonstrate the safety and efficacy of ethylene 
vinyl alcohol (EVOH) copolymer (Onyx ®; 
Medtronic, Inc, Minneapolis, MN) in non-CNS 
vascular pathologies.  
BACKGROUND 
• Onyx is an FDA-approved non-adhesive permanent 
liquid embolic for pre-operative embolization of 
cerebral arteriovenous malformations (AVMs)1. 
 
• Off-label use has gained recognition to treat a 
variety of peripheral pathologies most commonly: 
type II endoleaks2 and peripheral AVMs3. 
 
• Onyx is composed of an EVOH copolymer, DMSO, 
and micronized tantalum powder.  
 
• DMSO diffuses upon contact with blood allowing 
precipitation of EVOH. The copolymer solidifies 
from surface to center maintaining a liquid core.  
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References 
• This study demonstrates that Onyx is a safe and 
effective embolic agent to treat a variety of 
extracranial vascular pathologies. 
 
 
 
Fluoroscopic Images   
Fig. 1. 57 year-old male presented with hematemesis, melena, and persistent extravasation 
into the proximal duodenum after embolization with 4 interlock detachable coils. 
Fluoroscopic image reveals catheterization of the GDA with complete cessation of 
extravasation after embolization with Onyx 34.   
Fig. 2. 61 year-old male with congenital venous malformation of the right shoulder, axilla, 
and pectoralis muscle presents with swelling of the affected areas. Fluoroscopic image shows 
Onyx 18 and 34 and Truefill glue embolization of a large superficial lateral chest wall AVM. 
Subsequent surgical excision performed with <7ml of blood loss.   
Fig. 3. 53 year-old male s/p left partial nephrectomy presenting with hematuria. Image 
shows selective embolization with Onyx 34 of left renal artery third order branch 
pseudoaneurysm.  
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Fig. 4. 28 year-old male presenting with RUQ abdominal pain. Selective angiogram reveals 
presence of a distal left hepatic arterial branch pseudoaneurysm (A) with subsequent Onyx 
18 embolization (B).   
Fig. 5. 75 year-old male with enlarging infrarenal AAA sac s/p endovascular repair. 
Fluoroscopic image demonstrates embolization with Onyx 34 of a third order L4 lumbar 
artery causing the Type II endoleak. Of note, coil deployment was initially attempted to 
embolize this leak but proved to be technically challenging. 
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Conclusion   
• Performed a retrospective review of all cases that 
used Onyx between October 2010 and October 
2017 at a single tertiary care academic university 
urban hospital.  
 
• Choice of embolic agents was based on the 
operator’s decision for definitive treatment, 
preoperative embolization, or palliation. 
 
• Institutional review board approval was 
appropriately obtained. Data  was collected via 
EMR and PACS. Head and neck cases were 
excluded. 
 
• Analyzed demographic data, technical success, 
clinical success, complications, adjunct embolic 
agents used, and anatomic location. 
 
• May be expanded to nonvascular uses, e.g. closure 
fistulae refractory to surgery or in high risk 
patients, and to situations refractory to other 
agents. 
 
• Despite larger sample size, the data is 
retrospective. Future studies require randomized 
controlled setting or a noninferiority analysis 
comparing different embolic therapies. 
Discussion  
• 49 patients were identified who underwent 
embolization with Onyx for extracranial 
pathologies.  
 
• A total of 64 instances met our criteria. The 
incongruent number of cases compared to patients 
was secondary to multiple sessions for some 
patients.  
 
• Such cases included: venous malformation, 
arteriovenous malformations, and type II 
endoleaks.  
 
• Technical success was achieved in 100% of cases. 
The clinical success rate was 98%.  
 
• Among all 64 cases, only one complication had 
occurred with nontarget embolization of a renal 
pseudoaneurysm status post nephrectomy. 
 
Results  
Table 1. Characteristics of Onyx embolization cases. 
Indications for treatment, n = 54 (%)  Onyx concentration used, n = 54 (%)  
Primary treatment 42 (78) 18 13 (24) 
Pre-surgical devascularization 6 (11) 34 35 (65) 
Palliative or symptomatic relief 6 (11) Both 6 (11) 
Major anatomic region, n = 54  Adjunct embolic agent used, n = 54 (%)  
Endoleak repair  18 None (Onyx only) 33 (61) 
Upper and lower extremity arteries  11 Coils 13 (24) 
Pelvic arterial system  9 NBCA 4 (7) 
Gastrointestinal arterial system  7 Sotradecol foam 2 (4) 
Renal artery branches  4 Embospheres 1 (2) 
Venous malformation  4 Coils & Gel foam 1 (2) 
Pulmonary artery  1 
ADVANTAGES LIMITATIONS 
 “Lava-like” consistency for precise 
embolization of tortuous, complex vessels 
 Cost prohibitive 
 Varying EVOH concentrations and 
viscosities for distal targets or different flow 
rates4 
 Nontarget embolization 
 Non-absorbable and cohesive properties   DMSO-compatible microcatheters 
 Longer injection time, better operator 
control 
 DMSO side effects (foul breath, 
vasospasm, respiratory distress)5 
 Strong fluoroscopic visibility 
 Independent of coagulation cascade 
